{
    "Patient Information": {
        "Patient ID": "N/A",
        "Patient Name": "Michael Bennett",
        "Date of Birth": "1966-07-03",
        "Age": 58,
        "Gender": "Female",
        "Contact Information": "N/A",
        "Address": "N/A"
    },
    "Diagnosis Information": {
        "Diagnosis Center": "Jones, Obrien and Williams",
        "Doctor Name": "Dr. Michelle Wilson",
        "Accession Number": "5903",
        "Date of Diagnosis": "2023-12-18",
        "Date of Report Issuance": "2023-12-25",
        "CLIA Number": "14D2114007",
        "Laboratory Medical Director ": "Dr. Christopher Perez",
        "Method of Analysis": "Not explicitly stated, assumed NGS",
        "Pipeline Version (Report Version)": "3.2.0"
    },
    "Cancer Information": {
        "Cancer Type": "Adenocarcinoma",
        "Cancer Stage": "Not explicitly stated",
        "Cancer Grade": "Not explicitly stated",
        "Cancer Location in the Body": "Prostate",
        "Tumor Specimen Source": "Prostate",
        "Tumor Percentage in Sample": "78%",
        "Normal Specimen Source": "Blood",
        "Date of Tumor Sample Collection": "2023-12-23",
        "Date Tumor Sample Received": "2023-12-23",
        "Date of Normal Sample Collection": "2023-12-24",
        "Date Normal Sample Received": "2023-12-24"
    },
    "Biomarkers": {
        "General Biomarkers": {
            "Microsatellite Instability (MSI)": "High",
            "Tumor Mutational Burden (TMB)": "33 m/Mb",
            "Tumor Mutational Burden Percentile": "8%",
            "Loss of Heterozygosity (LOH)": "N/A",
            "Mismatch Repair (MMR) Status": "N/A",
            "PDL1 Expression": "N/A",
            "EBV (Epstein-Barr Virus) Status": "N/A",
            "Other Immunotherapy Markers": "N/A",
            "Low-Coverage Regions": [
                "ARHGAP45",
                "PAX5"
            ]
        },
        "Gene Mutations": [
            {
                "Gene Name": "CTNNB1",
                "DNA Mutation Description": "c.101G>T",
                "Protein Variant": "p.T41I",
                "Mutation Type": "Stopgain",
                "Functional Impact": "LOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "20.35%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Potentially Actionable",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "IDH1",
                "DNA Mutation Description": "c.395G>T",
                "Protein Variant": "p.S45P",
                "Mutation Type": "Missensevariant(exon2)",
                "Functional Impact": "GOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "7.96%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Biologically Relevant",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "JAK2",
                "DNA Mutation Description": "c.1848_1849delinsCT",
                "Protein Variant": "p.S37C",
                "Mutation Type": "Spliceregionvariant",
                "Functional Impact": "LOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "12.16%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Biologically Relevant",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "NOTCH1",
                "DNA Mutation Description": "c.3587G>A",
                "Protein Variant": "p.R132L",
                "Mutation Type": "Spliceregionvariant",
                "Functional Impact": "LOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "17.91%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Biologically Relevant",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "MPL",
                "DNA Mutation Description": "c.1544G>T",
                "Protein Variant": "p.T875N",
                "Mutation Type": "Missensevariant(exon2)",
                "Functional Impact": "GOF",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "8.17%",
                "Transcript ID": "N/A",
                "Somatic or Germline": "Somatic",
                "Potentially Actionable or Biologically Relevant": "Biologically Relevant",
                "Analyte": "DNA",
                "Method of Detection ": "N/A",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            }
        ],
        "Immunochemistry Biomarkers": []
    },
    "Therapeutic Information": {
        "FDA-Approved Therapies for Current Diagnosis": [
            {
                "Therapy Name": "KRAS G12C Inhibitors",
                "Therapy Type": "targeted therapy",
                "Medication": "Sotorasib",
                "Evidence Source": "NCCN, Consensus, Non-Small Cell Lung Cancer, MSK OncoKB, Level 1",
                "Associated Biomarker": {
                    "Biomarker Name": "KRASp.G12C G12C-GOF",
                    "Positively/Negatively Associated": "N/A"
                }
            }
        ],
        "FDA-Approved Therapies for Other Indications": [
            {
                "Therapy Name": "KRAS G12C Inhibitors",
                "Therapy Type": "targeted therapy",
                "Medication": "Sotorasib",
                "Evidence Source": "NCCN, Consensus, Non-Small Cell Lung Cancer, MSK OncoKB, Level 1",
                "Associated Biomarker": {
                    "Biomarker Name": "KRASp.G12C G12C-GOF",
                    "Positively/Negatively Associated": "N/A"
                }
            }
        ]
    },
    "Clinical Trials": [
        {
            "Trial Title": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "Phase 2",
            "Trial Location": "City, state - x mi",
            "Therapy Type": "N/A",
            "Medication": "N/A",
            "Associated Mutations": [
                "KRAS"
            ]
        },
        {
            "Trial Title": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "Phase 1/2",
            "Trial Location": "City, state - x mi",
            "Therapy Type": "N/A",
            "Medication": "N/A",
            "Associated Mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "Trial Title": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "Phase 1/2",
            "Trial Location": "City, state - x mi",
            "Therapy Type": "N/A",
            "Medication": "N/A",
            "Associated Mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "Variants of Unknown Significance (VUS)": [
        {
            "Gene Name": "ABL1",
            "DNA Alteration": "c.3113A>G",
            "Protein Variant": "p.A34V",
            "Mutation Type": "Stopgain",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "22.82%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "HRAS",
            "DNA Alteration": "c.35_36delinsTA",
            "Protein Variant": "p.G12D",
            "Mutation Type": "Frameshift",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "8.7%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "EZH2",
            "DNA Alteration": "c.1936T>G",
            "Protein Variant": "p.Y646F",
            "Mutation Type": "Frameshift",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "8.8%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "PDGFRB",
            "DNA Alteration": "c.3113A>G",
            "Protein Variant": "p.T681I",
            "Mutation Type": "Frameshift",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "1.01%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "JAK3",
            "DNA Alteration": "c.3113A>G",
            "Protein Variant": "p.L857P",
            "Mutation Type": "Frameshift",
            "Functional Impact": "GOF",
            "Variant Allele Fraction": "9.76%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "DNMT3A",
            "DNA Alteration": "c.2711C>T",
            "Protein Variant": "p.P904L",
            "Mutation Type": "Stopgain",
            "Functional Impact": "LOF",
            "Variant Allele Fraction": "2.83%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "MSH2",
            "DNA Alteration": "c.1906G>C",
            "Protein Variant": "p.A636P",
            "Mutation Type": "Spliceregionvariant",
            "Functional Impact": "GOF",
            "Variant Allele Fraction": "8.24%",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Somatic"
        },
        {
            "Gene Name": "BTK",
            "DNA Alteration": "c.3113A>G",
            "Protein Variant": "p.C481X",
            "Mutation Type": "Frameshift",
            "Functional Impact": "GOF",
            "Condition": "agent",
            "Exon Number": "N/A",
            "Transcript ID": "NM_001011645",
            "Somatic or Germline": "Germline"
        }
    ],
    "Additional Indicators": {
        "Prognostic Markers": {
            "description": "Unfavorable Prognosis",
            "recommendation": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "biomarker": "KRASp.G12C Gain-of-function"
        }
    }
}